Similar Items: Assessment of Interleukin-31 and Calprotectin in Immunocompromised Patients with Epstein-Barr Virus Infection
- Immunological Impact of Calprotectin and Interleukin-34 in Immunocompromised Patients with Chronic Cytomegalovirus Infection
- Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity
- Molecular Evaluation of Interleukin-8, Interleukin-27, and Vascular Endothelial Growth Factor Expression in Prostate Cancer Patients
- Treatment outcomes of Epstein-Barr virus associated nasopharyngeal carcinoma with three-dimensional conformal radiotherapy: A retrospective review
- Atypical reactive lymphoid hyperplasia : a 5 year study with analysis of 10 cases for latent Epstein-Barr virus infection by in situ hybridization and immunohistochemistry
- ATG Plus Post-Transplantation Cyclophosphamide Improves EBV-DNA Clearance and GVHD in Patients of Adult Chronic Active Epstein-Barr Virus Disease Undergoing Allogeneic HSCT